Table III.
Relative Odds of Toxicity among Elderly Stage IIIB and IV Non-small Cell Lung Cancer Patients Who Received Chemotherapy or Radiation Compared to Untreated Patients
| Stage IIIB | Stage IV | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type of Toxicity | RT Alone | Chemotherapy Alone | CRT | Chemotherapy | ||||||||
| Unadjusted OR1 (95% CI) |
Adjusted OR1 (95% CI) |
P value | Unadjusted OR1 (95% CI) |
Adjusted OR1 (95% CI) |
P value | Unadjusted OR1 (95% CI) |
Adjusted OR1 (95% CI) |
P value | Unadjusted OR1 (95% CI) |
Adjusted OR1 (95% CI) |
P value |
|
| Any toxicity | 2.8(2.0–3.8) | 2.6(1.9–3.7) | <0.0001 | 3.9(2.8–5.4) | 3.9(2.7–5.4) | <0.0001 | 5.7(4.3–7.7) | 5.9(4.3–8.1) | <0.0001 | 3.0(2.7–3.2) | 2.9(2.7–3.2) | <0.001 |
| Infection | 3.3(1.6–6.9) | 3.2(1.5–6.7) | 0.002 | 4.4(2.1–9.1) | 4.0(1.9–8.4) | 0.0003 | 8.6(4.5–16.6) | 8.8(4.5–17.4) | <0.0001 | 2.6(2.2–3.0) | 2.6(2.2–3.0) | <0.0001 |
| Neutropenia | 2.1(0.4–11.8) | 1.8(0.3–10.3) | 0.51 | 17.1(4.0–72.6) | 20.6(4.7–89.4) | <0.0001 | 22.7(5.5–92.9) | 23.9(5.7–99.8) | <0.0001 | 8.4(6.1–11.5) | 8.4(6.1–11.7) | <0.0001 |
| Fever | –1 | –2 | – | –2 | –2 | – | –2 | –2 | – | 4.2(2.6–6.8) | 3.2(1.9–5.4) | <0.0001 |
| Abnormal electrolytes or dehydration | 3.4(2.1–5.4) | 3.1(1.9–4.9) | <0.0001 | 4.1(2.6–6.6) | 4.0(2.5–6.5) | <0.0001 | 6.8(4.5–10.4) | 6.8(4.3–10.5) | <0.0001 | 2.4(2.2–2.7) | 2.5(2.2–2.8) | <0.0001 |
| Nausea, emesis or diarrhea | 1.9(0.6–5.8) | 1.4(0.4–4.3) | 0.57 | 3.9(1.4–10.8) | 3.5(1.2–10.2) | 0.02 | 3.6(1.4–9.4) | 2.9(1.1–8.1) | 0.04 | 3.9(3.0–5.2) | 3.9(2.9–5.2) | <0.0001 |
| Anemia or transfusion | 3.0(1.9–4.8) | 3.0(1.9–4.9) | <0.0001 | 3.8(2.4–6.2) | 4.0(2.5–6.6) | <0.0001 | 6.2(4.0–9.4) | 5.9(3.8–9.2) | <0.0001 | 3.4(3.0–3.9) | 3.4(3.0–3.9) | <0.0001 |
| Thrombocytopenia | 1.6(0.5–5.7) | 2.1(0.6–7.8) | 0.27 | 3.8(1.2–12.0) | 3.4(1.0–11.2) | 0.04 | 5.2(1.8–14.8) | 5.5(1.8–16.4) | 0.002 | 6.1(4.4–8.4) | 5.4(3.9–7.6) | <0.0001 |
| Renal failure | 1.6(0.5–5.7) | 1.9(0.5–7.2) | 0.32 | 1.4(0.3–5.5) | 1.4(0.3–5.8) | 0.69 | 4.3(1.5–12.4) | 4.9(1.6–15.0) | 0.005 | 1.5(1.2–1.9) | 1.6(1.3–2.1) | 0.0002 |
| Non-specific adverse events | –2 | –2 | – | –2 | –2 | – | –2 | –2 | – | 7.0(3.9–12.6) | 7.0(3.8–12.9) | <0.0001 |
| Radiation pneumonitis | –2 | –2 | – | –2 | –2 | – | –2 | –2 | – | –2 | –2 | |
| Esophagitis | 7.6(0.9–61.6) | 8.3(1.0–69.7) | 0.05 | 4.1(0.4–39.4) | 5.3(0.5–55.2) | 0.16 | 48.5(6.7–350.5) | 48.9(6.7–358.0) | 0.0001 | –2 | –2 | |
1
OR (Odds ratio) compared to untreated stage IIIB or IV patients, as appropriate
RT: radiation therapy; CRT: chemoradiation therapy; CI: confidence interval
2
Results not reported due to lack of model convergence